MPM BIOVENTURES 2018, L.P. (CIK 1729505) reported 17 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2026-09-09). Recent activity: Sell TRDA (38,500 shares), Sell TRDA (192,500 shares), Sell TRDA (28,837 shares), Sell TRDA (29,088 shares), Sell TRDA (25,131 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 38,500 | $273,735 |
| 2026-09-09 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 192,500 | $1.4M |
| 2026-09-09 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 28,837 | $205,608 |
| 2026-09-03 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 29,088 | $205,361 |
| 2026-09-03 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 25,131 | $180,692 |
| 2026-09-03 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 32,263 | $231,326 |
| 2026-08-31 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 38,922 | $280,238 |
| 2026-08-31 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 3,733 | $26,168 |
| 2026-08-31 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 44,259 | $309,370 |
| 2026-08-26 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 21,623 | $158,713 |
| 2026-08-26 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 26,522 | $199,976 |
| 2026-08-26 | Entrada Therapeutics, Inc. (TRDA) | 10% Owner | Sell | 14,569 | $102,857 |
| 2026-01-14 | Aktis Oncology, Inc. (AKTS) | 10% Owner | Buy | 1.3M | $0 |
| 2026-01-14 | Aktis Oncology, Inc. (AKTS) | 10% Owner | Buy | 5.9M | $0 |
| 2026-01-14 | Aktis Oncology, Inc. (AKTS) | 10% Owner | Buy | 1.6M | $0 |
| 2026-01-14 | Aktis Oncology, Inc. (AKTS) | 10% Owner | Buy | 1.1M | $20.0M |
| 2025-05-15 | iTeos Therapeutics, Inc. (ITOS) | Insider | Sell | 630,191 | $5.1M |
来源：SEC Form 4 申报文件 · 截至 2026-09-09